SCHEMBL2270436

SCHEMBL2270436

CC(C)(C)Nc1nc(Cl)nc2c1CCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
USP2 O75604 1/20 0.38
CYP1A2 P05177 2/20 0.37
PDE4A P27815 1/20 0.37
CYP2C19 P33261 1/20 0.37
GAA P10253 2/20 0.35
KMT2A Q03164 2/20 0.33
MAPK1 P28482 2/20 0.33
MEN1 O00255 1/20 0.33
ACHE P22303 1/20 0.33
BPTF Q12830 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
KDM4E B2RXH2 1/20 0.32
IGF1R P08069 2/20 0.32
HTT P42858 2/20 0.32
POLB P06746 1/20 0.32
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
NSD2 O96028 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11290218 0.80 HTT (0.45) LMNAUSP2CYP1A2GAAKMT2A
SCHEMBL6457209 0.77 HTT (0.48) LMNAUSP2CYP1A2GAAKMT2A
SCHEMBL23976182 0.75 LATS1 (0.38) USP2CYP1A2GAAKMT2AMAPK1
SCHEMBL15831720 0.75 HTT (0.47) LMNACYP1A2PDE4AGAAKMT2A
SCHEMBL30225183 0.74 MEN1 (0.41) USP2CYP1A2GAAKMT2AMAPK1
SCHEMBL23975703 0.74 MEN1 (0.41) USP2CYP1A2GAAKMT2AMAPK1
SCHEMBL14090670 0.73 USP2 (0.38) SMN1; SMN2USP2CYP1A2CYP2C19KMT2A
SCHEMBL23975716 0.72 NPSR1 (0.40) USP2CYP1A2GAAKMT2AMEN1
SCHEMBL23975822 0.72 NPSR1 (0.40) USP2CYP1A2GAAKMT2AMEN1
SCHEMBL24702114 0.72 NPSR1 (0.32) USP2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989463-B2 Biccyclic compounds as GATA modulators DR. REDDY'S LABORATORIES LIMITED (IN) 2011-08-02 US disclosed
US-7989463-B2 Biccyclic compounds as GATA modulators DR. REDDY'S LABORATORIES LIMITED (IN) 2011-08-02 US disclosed
US-7989463-B2 Biccyclic compounds as GATA modulators DR. REDDY'S LABORATORIES LIMITED (IN) 2011-08-02 US disclosed
US-20100144731-A1 Novel Biccyclic Compounds As GATA Modulators DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
US-20100144731-A1 Novel Biccyclic Compounds As GATA Modulators DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
US-20100144731-A1 Novel Biccyclic Compounds As GATA Modulators DR. REDDY'S LABORATORIES LTD. (IN) 2010-06-10 US disclosed
WO-2010028174-A1 NOVEL BICCYCLIC COMPOUNDS AS GATA MODULATORS DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144731-A1 Novel Biccyclic Compounds As GATA Modulators GATAD2A, GATAD2B, RUNX1 LMNA 4083/4885SMN1; SMN2 4498/4885USP2 3497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.